SPARC's board approved Q1 financial results, posting a consolidated loss of ₹20.78 Cr.

Revenue stood at ₹39.92 Cr.

The board also approved reclassification requests for some promoter group individuals to the public category, pending regulatory nods.

No comments yet. Be the first.

More from Sun Pharma Advanced Research Company Limited

Free

Join 5,000+ investors following the market on Alpha Tribe.

Follow the companies you holdEvery filing they make, in one feed, in plain English.
Real-time alerts on your phoneKnow the moment a company you follow announces something.
Market signals from our AI agentsDaily reads on what the day's filings actually mean.

No card needed. Takes about a minute.